2026-01-24 - Analysis Report
**Company Overview**
Merck is a global healthcare company that discovers, develops, manufactures, and markets a wide range of pharmaceuticals, vaccines, and animal health products.

**Return Rate Comparison**
The return rate of Merck (MRK) is 70.14%, while the return rate of S&P 500 (VOO) is 126.41%. The degree of divergence on the last day of the data is -56.30 ($126.41 - $70.14), which indicates a negative difference of 56.30%.

**Alpha, Beta Analysis**
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 37.0% | 15.3% | 25.0% | 0.7 | 182.1B |
| 2017-2019  | 39.0% | 15.3% | 14.0% | 0.7 | 216.8B |
| 2018-2020  | 29.0% | 25.1% | 4.0% | 0.7 | 195.0B |
| 2019-2021  | 0.0% | 25.1% | -65.0% | 0.6 | 191.4B |
| 2020-2022  | 43.0% | 23.0% | 36.0% | 0.5 | 277.1B |
| 2021-2023  | 51.0% | 19.3% | 30.0% | 0.3 | 272.3B |
| 2022-2024  | 18.0% | 25.1% | -11.0% | 0.3 | 248.5B |
| 2023-2025  | -11.0% | 39.7% | -86.0% | 0.3 | 262.9B |

**Recent Stock Price Fluctuations**
- Close: $108.18
- Last-market: -$0.92
- 5-day SMA: $109.35
- 20-day SMA: $108.51
- 60-day SMA: $99.90

**RSI, PPO Index, and Delta_Previous_Relative_Divergence**
- Market Risk Indicator (MRI): 0.70
- RSI: 54.82
- PPO: -0.45
- Hybrid Signal: Buy (Cash 0%)
Risk Level: Medium (MRI 0.70)
- Recent (20 days) relative divergence change: -2.40 (-): worsening
- 7-day Rank change: 97 (+): rank up
- 7-day Dynamic Expected Return change: 25.20 (+): improving
- Expected Return (%): -4.60%

**Recent News & Significant Events**
- [2026-01-23] Why Analysts See Merck (MRK) Differently After The Latest Price Target Reset - Yahoo Finance
- [2026-01-22] Merck Stock Shares $91 Bil Success With Investors - Trefis
- [2026-01-23] Merck & Co stock: Defensive giant tests investor patience as pipeline hopes fight valuation fears - AD HOC NEWS
- [2026-01-21] Merck & Co., Inc. $MRK Stock Position Boosted by Joel Isaacson & Co. LLC - MarketBeat
- [2026-01-23] Merck Weighs mRNA Breakthrough And Revolution Deal Against Oncology Valuation - simplywall.st
- [2026-01-20] New Analyst Forecast: $MRK Given $120 Price Target - Quiver Quantitative

**Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 115.11 / 135.00 / 83.00

**Recent Earnings Analysis**
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

**Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

**Capital and Profitability**
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

**Comprehensive Analysis**
Based on the provided data, Merck (MRK) has experienced fluctuations in its return rate, which is lower than that of the S&P 500 (VOO) by -56.30. The Alpha, Beta analysis shows relatively stable growth with a CAGR of 37.0% to 51.0% and a Beta of 0.3 to 0.7 across different time periods. The recent stock price fluctuation indicates a slight decline, with a close of $108.18 and a 5-day SMA of $109.35. The RSI and PPO index suggest a moderate risk level with a Market Risk Indicator of 0.70. The Expected Return (%)) is -4.60%. The recent news and significant events indicate a mixed sentiment, with analysts seeing Merck differently after the latest price target reset and weighing mRNA breakthrough and Revolution deal against oncology valuation. The Analyst Opinions suggest a Buy key with a mean of 1.90. The Recent Earnings Analysis shows stable EPS and revenue growth. The Financial Information, including Revenue and Profitability and Capital and Profitability, indicates a strong equity and ROE across different time periods.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.